Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Of Subcutaneous Amifostine For Reversal Of Persistent Paclitaxel-Induced Peripheral Neuropathy

NCT00078845 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00078845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00078845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Of Subcutaneous Amifostine For Reversal Of Persistent Paclitaxel-Induced Peripheral Neuropathy
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
May 31, 2007
Enrollment
24 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lung cancer, neurotoxicity, ovarian cancer, prostate cancer, unspecified adult solid tumor, protocol specific